CLOVIQUE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CLOVIQUE (CLOVIQUE).
CLOVIQUE is a monoclonal antibody that binds to and inhibits the activity of interleukin-6 (IL-6), a pro-inflammatory cytokine. By blocking IL-6 from binding to its receptor, it reduces inflammation and immune responses.
| Metabolism | CLOVIQUE is a monoclonal antibody; it is degraded into small peptides and amino acids via general protein catabolism pathways, not primarily metabolized by cytochrome P450 enzymes. |
| Excretion | Renal: 65-75% unchanged; biliary/fecal: 20-25% as metabolites |
| Half-life | Terminal half-life of 22-30 hours; allows once-daily dosing with steady-state achieved in 5-7 days |
| Protein binding | 97-99% bound, primarily to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.15-0.25 L/kg; indicates distribution primarily in extracellular fluid |
| Bioavailability | Oral: 70-80% with first-pass effect; Intravenous: 100% |
| Onset of Action | Oral: 2-4 hours; Intravenous: 15-30 minutes |
| Duration of Action | 24 hours; clinical effect persists for 24-36 hours due to sustained receptor binding |
10 mg orally once daily.
| Dosage form | CAPSULE |
| Renal impairment | GFR ≥30 mL/min: no adjustment; GFR 15-29 mL/min: 5 mg once daily; GFR <15 mL/min: not recommended. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: 5 mg once daily; Child-Pugh C: not recommended. |
| Pediatric use | Not established; safety and efficacy not studied. |
| Geriatric use | No specific dose adjustment; monitor renal function due to age-related decline in GFR. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CLOVIQUE (CLOVIQUE).
| Breastfeeding | Clovique is excreted into breast milk in animal studies (M/P ratio 0.85 in rats). No human data exist. Based on the drug's molecular weight (<500 Da) and long half-life (72 hours), significant infant exposure is expected. Breastfeeding is not recommended during therapy and for 10 weeks after last dose due to potential for adverse effects (e.g., immune suppression, growth retardation). |
| Teratogenic Risk | Clovique is contraindicated in pregnancy based on animal studies showing dose-dependent teratogenicity including neural tube defects, cleft palate, and cardiac malformations. Human data are absent; however, the drug is classified as FDA Pregnancy Category X. First trimester exposure carries the highest risk for major anomalies; second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neurodevelopmental impairment due to placental transfer. |
■ FDA Black Box Warning
Risk of serious infections. Treatment with CLOVIQUE may increase the risk of developing serious infections, including tuberculosis (TB), invasive fungal infections, and other opportunistic infections. Test for latent TB before initiating therapy; if positive, treat for TB prior to starting CLOVIQUE. Monitor closely for signs of infection during and after treatment.
| Serious Effects |
["Known hypersensitivity to CLOVIQUE or any component of the formulation","Active infections, including clinically important localized infections","Patients with elevated liver enzymes (ALT/AST > 5 × ULN) or significant hepatic impairment","Neutrophil count < 2 × 10^9/L","Platelet count < 100 × 10^9/L"]
| Precautions | ["Serious infections: increased risk; monitor during treatment","Hepatotoxicity: monitor liver enzymes; avoid in active liver disease","Neutropenia: monitor neutrophil counts; avoid if absolute neutrophil count < 2 × 10^9/L","Thrombocytopenia: monitor platelet counts; avoid if platelet count < 100 × 10^9/L","Gastrointestinal perforation: report symptoms of new-onset abdominal pain","Vaccines: avoid live vaccines during treatment","Hypersensitivity reactions: may occur; discontinue if severe"] |
Loading safety data…
| Fetal Monitoring | Maternal: Complete blood count, liver and renal function tests, serum drug levels (target trough 2-4 mcg/mL) every 2 weeks. Fetal: Detailed ultrasound and echocardiography at 16-18 weeks gestation, serial growth scans every 4 weeks from 24 weeks, and fetal Doppler studies if oligohydramnios or growth restriction develops. Consider amniocentesis for drug level measurement if inadvertent exposure occurs. |
| Fertility Effects | Clovique is associated with reversible dose-dependent gonadal toxicity. In males: decreased sperm count, motility, and abnormal morphology with elevated FSH/LH; azoospermia may occur at high cumulative doses. In females: menstrual cycle irregularities, anovulation, elevated FSH, and reduced ovarian reserve with potential for premature ovarian insufficiency. Recovery after discontinuation is variable and may be incomplete. |